Valoctocogene Roxaparvovec基因治疗A型血友病
这项开放标签、单组、多中心3期研究评估了valoctocogene roxaparvovec在重症A型血友病男性中的疗效与安全性。134例受试者接受单次6×10¹³载体基因组/公斤体重输注后,第49至52周凝血因子VIII活性平均较基线升高41.9 IU/dL(95%CI 34.1至49.7),年化凝血因子VIII浓缩物用量和治疗性出血率分别降低98.6%和83.8%。全部受试者发生至少1起不良事件,16.4%报告严重不良事件。
要点
- 单次输注后第49至52周,132例HIV阴性受试者因子VIII活性平均升高41.9 IU/dL(95%CI 34.1至49.7;P<0.001)。
- 112例来自前瞻性非干预研究的受试者中,年化因子VIII浓缩物用量降低98.6%,治疗性出血率降低83.8%(两项比较P均<0.001)。
- 134例中22例(16.4%)报告严重不良事件,115例(85.8%)出现丙氨酸氨基转移酶升高并用免疫抑制剂处理。
核心结论
- 在重症A型血友病患者中,valoctocogene roxaparvovec治疗可产生内源性因子VIII,并较因子VIII预防治疗显著减少出血和因子VIII浓缩物用量。
研究设计与样本
- 开放标签、单组、多中心3期研究,评估valoctocogene roxaparvovec在重症A型血友病(因子VIII水平≤1 IU/dL)男性中的疗效与安全性。
- 纳入年龄≥18岁、无预先存在抗AAV5抗体、无因子VIII抑制物发生史且此前接受因子VIII浓缩物预防治疗的受试者,单次输注6×10¹³载体基因组/公斤体重。
- 主要终点为输注后第49至52周因子VIII活性(发色底物法测定)较基线的变化;次要终点包括年化因子VIII浓缩物用量和出血率的变化;安全性以不良事件和实验室检查结果评估。
主要发现
- 共134例受试者接受输注并完成超过51周随访。
- 132例HIV阴性受试者第49至52周因子VIII活性平均较基线升高41.9 IU/dL(95%CI 34.1至49.7;P<0.001;中位变化22.9 IU/dL;四分位距10.9至61.3)。
- 112例来自前瞻性非干预研究的受试者中,输注后第4周后年化因子VIII浓缩物用量和治疗性出血率分别降低98.6%和83.8%(两项比较P均<0.001)。
- 全部受试者发生至少1起不良事件;134例中22例(16.4%)报告严重不良事件。
- 134例中115例(85.8%)出现丙氨酸氨基转移酶升高并用免疫抑制剂处理;其他最常见不良事件为头痛(38.1%)、恶心(37.3%)和天冬氨酸氨基转移酶升高(35.1%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an adeno-associated virus 5 (AAV5)-based gene-therapy vector containing a coagulation factor VIII complementary DNA driven by a liver-selective promoter. The efficacy and safety of the therapy were previously evaluated in men with severe hemophilia A in a phase 1-2 dose-escalation study. METHODS: We conducted an open-label, single-group, multicenter, phase 3 study to evaluate the efficacy and safety of valoctocogene roxaparvovec in men with severe hemophilia A, defined as a factor VIII level of 1 IU per deciliter or lower. Participants who were at least 18 years of age and did not have preexisting anti-AAV5 antibodies or a history of development of factor VIII inhibitors and who had been receiving prophylaxis with factor VIII concentrate received a single infusion of 6×1013 vector genomes of valoctocogene roxaparvovec per kilogram of body weight. The primary end point was the change from baseline in factor VIII activity (measured with a chromogenic substrate assay) during weeks 49 through 52 after infusion. Secondary end points included the change in annualized factor VIII concentrate use and bleeding rates. Safety was assessed as adverse events and laboratory test results. RESULTS: Overall, 134 participants received an infusion and completed more than 51 weeks of follow-up. Among the 132 human immunodeficiency virus-negative participants, the mean factor VIII activity level at weeks 49 through 52 had increased by 41.9 IU per deciliter (95% confidence interval [CI], 34.1 to 49.7; P<0.001; median change, 22.9 IU per deciliter; interquartile range, 10.9 to 61.3). Among the 112 participants enrolled from a prospective noninterventional study, the mean annualized rates of factor VIII concentrate use and treated bleeding after week 4 had decreased after infusion by 98.6% and 83.8%, respectively (P<0.001 for both comparisons). All the participants had at least one adverse event; 22 of 134 (16.4%) reported serious adverse events. Elevations in alanine aminotransferase levels occurred in 115 of 134 participants (85.8%) and were managed with immune suppressants. The other most common adverse events were headache (38.1%), nausea (37.3%), and elevations in aspartate aminotransferase levels (35.1%). No development of factor VIII inhibitors or thrombosis occurred in any of the participants. CONCLUSIONS: In patients with severe hemophilia A, valoctocogene roxaparvovec treatment provided endogenous factor VIII production and significantly reduced bleeding and factor VIII concentrate use relative to factor VIII prophylaxis. (Funded by BioMarin Pharmaceutical; GENEr8-1 ClinicalTrials.gov number, NCT03370913.).
引用
- Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022. PMID: 35294811. doi:10.1056/NEJMoa2113708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。